Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;45(1):29-41.
doi: 10.1007/s00281-022-00973-1. Epub 2022 Nov 21.

Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy

J Wlosik  1   2 , S Fattori  3   4 , P Rochigneux  3   4   5 , A Goncalves  5   6 , D Olive #  3   4 , A S Chretien #  7   8
Affiliations
Review

Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy

J Wlosik et al. Semin Immunopathol. 2023 Jan.

Abstract

First-line immunotherapy in non-small-cell lung cancer largely improved patients' survival. PD-L1 testing is required before immune checkpoint inhibitor initiation. However, this biomarker fails to accurately predict patients' response. On the other hand, immunotherapy exposes patients to immune-related toxicity, the mechanisms of which are still unclear. Hence, there is an unmet need to develop clinically approved predictive biomarkers to better select patients who will benefit the most from immune checkpoint inhibitors and improve risk management. Single-cell technologies provide unprecedented insight into the tumor and its microenvironment, leading to the discovery of immune cells involved in immune checkpoint inhibitor response or toxicity. In this review, we will underscore the potential of the single-cell approach to identify candidate biomarkers improving non-small-cell lung cancer patients' care.

Keywords: Immunotherapy; NSCLC; Predictive biomarkers; Single-cell technologies; irAEs.

PubMed Disclaimer

Conflict of interest statement

D. O. is a cofounder and shareholder of ImCheck Therapeutics, Alderaan Biotechnology and Emergence Therapeutics and has research funds from ImCheck Therapeutics, Alderaan Biotechnology, Cellectis and Emergence Therapeutics. The other authors declare no conflicts of interest.

References

    1. Barta JA, Powell CA, Wisnivesky JP (2019) Global epidemiology of lung cancer. Ann Glob Health 85(1):8. 10.5334/aogh.2419 - PMC - PubMed
    1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. doi: 10.1056/NEJMoa1501824. - DOI - PubMed
    1. Garon EB. The race for combined checkpoint inhibition in NSCLC. Lancet Oncol. 2016;17(3):259–260. doi: 10.1016/S1470-2045(15)00580-X. - DOI - PubMed
    1. Ellis PM, Vella ET, Ung YC. Immune checkpoint inhibitors for patients with advanced non–small-cell lung cancer: a systematic review. Clin Lung Cancer. 2017;18(5):444–459.e1. doi: 10.1016/j.cllc.2017.02.001. - DOI - PubMed
    1. Garon EB, Hellmann MD, Rizvi NA et al (2019) Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I keynote-001 study. JCO JCO.19.00934. 10.1200/JCO.19.00934 - PMC - PubMed

Publication types

MeSH terms